The 2025 National Conference on Drug Registration Management and Post Market Supervision was held in Jinan, Shandong Province from February 18th to 19th. The meeting is guided by Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, fully implements the spirit of the 20th National Congress of the Communist Party of China and the 2nd and 3rd Plenary Sessions of the 20th Central Committee, implements the requirements of the National Conference on Drug Supervision and Administration, summarizes the work in 2024, analyzes the current situation, and studies and deploys key tasks for 2025. Huang Guo, member of the Party Group and Deputy Director of the National Medical Products Administration, attended the meeting and delivered a speech.

The meeting pointed out that in 2024, the entire system will take the initiative and deepen reforms in accordance with the work ideas of "emphasizing politics, strengthening supervision, ensuring safety, promoting development, and benefiting people's livelihoods", effectively promoting the development of new quality pharmaceutical productivity; Comprehensively improve drug standards, optimize review and approval requirements, accelerate the launch of a large number of new and good drugs, and better meet the medication needs of the people; Strengthen the supervision of high-risk drugs and selected drugs in centralized procurement, strictly investigate and punish illegal and irregular behaviors, and successfully conclude the action to consolidate and improve drug safety; Move the checkpoint forward and prevent potential risks, effectively preventing and resolving drug safety hazards; Deepen the construction of intelligent supervision, improve supporting laws and regulations, and continuously enhance drug supervision capabilities. The stable and positive trend of drug safety has been further consolidated, the driving force for high-quality development of the pharmaceutical industry has become stronger, and the capacity foundation of the modern drug regulatory system has become more solid, effectively ensuring the safety and effectiveness of medication for the people.

The meeting emphasized that 2025 is the year when the 14th Five Year Plan comes to an end and the year when the comprehensive deepening of drug regulatory reform begins again. We must focus on the "three highlights" and solidly do a good job in various aspects: first, we must highlight the prevention and resolution of safety risks and hidden dangers in all aspects, continuously strengthen the supervision of key areas such as centralized procurement of selected drugs, commissioned production of drugs, and online sales, strengthen risk monitoring and inspection law enforcement, and ensure high-level safety; Secondly, we must highlight the full chain to stimulate innovation vitality in the pharmaceutical industry, fully implement the reform measures of "Opinions on Deepening the Reform of Drug and Medical Device Supervision to Promote the High quality Development of the Pharmaceutical Industry", continue to strengthen the supervision of drug clinical trials, give full play to the leading role of drug standards, continuously promote the improvement of generic drug quality, and promote high-quality development; We must highlight the comprehensive improvement of the capabilities of various levels and types of regulatory agencies, accelerate the construction of a unified national working mechanism, strengthen the capacity building of inspectors, continue to promote intelligent drug supervision, and promote efficient supervision.

The main responsible officials of the Drug Registration Department and the Drug Supervision Department of the National Medical Products Administration will make specific arrangements for the key work of drug registration management and post market supervision in 2025. The National Medical Products Administration's Advanced Research Institute and provincial (municipal) drug regulatory bureaus such as Beijing, Tianjin, Shanghai, Jiangsu, Shandong, Hunan, Guangdong, and Chongqing made exchange speeches.

The heads of drug supervision work and relevant departments of the drug supervision bureaus of various provinces (regions, cities) and Xinjiang Production and Construction Corps, the Health Bureau of the Logistics Support Department of the Central Military Commission, relevant departments and directly affiliated units of the National Medical Products Administration attended the meeting.